Файл: Рекомендации-диабетическая-нефропатия.pdf

59.Laffel LM, McGill JB, Gans DJ. The beneficial effect ofangiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995 Nov;99(5):497-504.

60.Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G,Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.

61.Mogensen CE. Diabetic nephropathy: evidence for renoprotection and practice. Heart. 2000 Sep;84 Suppl 1:i26-8

62.Mogensen CE. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. J Renin Angiotensin Aldosterone Syst. 2000 Sep;1(3):234-9.

63.Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME.Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000 Dec9;321(7274):1440-4.

64.Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipidmodulation in insulindependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications. 2001 May-Jun;15(3):113-9.

65.Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on theprogression of renal disease: a meta-analysis. Kidney Int. 2001 Jan;59(1):260-9.

66.Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16.

67.Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med. 1999 Nov;16(11):918-25.

68.Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of

incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.

15;314(7083):783-8.

69.Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J,

Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators.Albuminuria and risk

of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

70.Reichard P et al. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. (1993) http://care.diabetesjournals.org/content/36/Supplement_1/S4.full

71.Bakris GL et al. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. (1998)